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While Clostridium difficile infection (CDI) has come to prominence as major epidemics have occurred in North
America and Europe over the recent decade, awareness and surveillance of CDI in Asia have remained poor.
Limited studies performed throughout Asia indicate that CDI is also a significant nosocomial pathogen in this
region, but the true prevalence of CDI remains unknown. A lack of regulated antibiotic use in many Asian countries
suggests that the prevalence of CDI may be comparatively high. Molecular studies indicate that ribotypes 027 and
078, which have caused significant outbreaks in other regions of the world, are rare in Asia. However, variant toxin
A-negative/toxin B-positive strains of ribotype 017 have caused epidemics across several Asian countries. Ribotype
smz/018 has caused widespread disease across Japan over the last decade and more recently emerged in Korea.
This review summarises current knowledge on CDI in Asian countries.
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Clostridium difficile causes infection ranging from mild
diarrhoea to pseudomembranous colitis (PMC), prima-
rily in older age patients who have been exposed to anti-
biotics. Epidemics of C. difficile infection (CDI) have
occurred in North America and Europe over recent de-
cades and the epidemiology of CDI in these regions is
well-documented. These epidemics have demonstrated
the need for surveillance of the international movement
of C. difficile strains [1]. Circulating strains in Asia, as in
other regions, have the potential to spread internatio-
nally, warranting close monitoring of the prevalence and
molecular epidemiology of CDI in the region. Indeed,
it is likely that the variant toxin A-negative/ toxin
B-positive (A-B+) ribotype 017 C. difficile strain origi-
nated in Asia. One particular clindamycin-resistant
ribotype 017 strain of apparent clonal origin has domi-
nated international typing studies of A-B+ strains and has
been the cause of epidemics in Canada, the Netherlands
and Ireland [2-4]. Unfortunately, limited data are available
on CDI in Asia. A recent survey found that awareness of
CDI in physicians is poor in Asia, with underestimation of* Correspondence: collid04@student.uwa.edu.au
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currence rates [5]. In addition, comprehensive culture
and toxin testing for C. difficile are lacking in many
Asian hospitals. As a consequence, reports of C. difficile
are rare in Asia, so data on prevalence and circulating
strains are limited. What reports are available on Asian
countries are described here.
Literature search and selection strategy
PubMed searches were performed for publications prior
to 1 May 2013 with the term “Clostridium difficile” com-
bined with specific Asian country names. A search for
“Clostridium difficile” was also performed on the
Wanfang and KoreaMed databases. Manual searches of
cited references of these articles were performed and




No English language reports were found on the preva-
lence of CDI in Japan. However, molecular typing stu-
dies have provided some epidemiological information
since the 1990s. A variety of typing techniques have been
employed in Japan, including tcdA and tcdB character-
isation [6,7], pulsed field gel electrophoresis (PFGE) [8],Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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slpA typing [10]. Application of molecular typing tech-
niques has identified A-B+ strains in regions across Japan
[6,11-14]. PCR typing of tcdA on six A-B+ strains from
Japan and Indonesia identified indistinguishable repea-
ting sequences with two deletions (1,548 and 273 nucle-
otides in size) [7]. A later study also grouped A-B+ strains
from Japan and Indonesia, as toxinotype VIII and ribotype
fr/017, with several subtypes identified by PFGE [15].
Several ribotyping studies have been performed, indi-
cating predominance of ribotype “smz” over the past
decade [8,16,17]. A 5-year study in a Tokyo hospital
followed the proliferation of ribotype “smz”, peaking in
2004 (64% of cases) [16]. Ribotype “smz” is recognised
internationally as ribotype 018 (personal observation),
and three major subtypes have been identified within
Japan by slpA typing, two of which are widespread
[10,18]. Ribotype 018 strains have caused CDI recently in
Korea [19], Austria, Spain and Slovenia [20], and have
been responsible for outbreaks of disease in Italy since
2007 [21]. Other common ribotypes were 014, 002 and
001 [14,16,17]. Ribotype 027, which has caused wide-
spread epidemics in North America and Europe, has been
reported only occasionally in Japan [16].
Korea
A country-wide survey of 17 tertiary hospitals in Korea
from 2004 to 2008 found that the incidence of CDI
increased from 1.7/1,000 adult admissions to 2.7/1,000
admissions [22]. Diagnostic methods were not reported,
and may have differed between sites or over time, con-
tributing to these apparent increases.
Risk factors for recurrent CDI included antibiotic the-
rapy, anaemia, and tube feeding in one study [23], while
another found proton pump inhibitor (PPI) use alone
was associated with recurrent disease [24]. One study
found that the proportion of community-acquired CDI
(CA-CDI) among all CDI cases within a Busan hospital
was 7.1% [25], while another reported that 59.4% of
cases of CDI presenting at the emergency department of
a Seoul hospital were community-acquired [26].
Variant A-B+ strains have been common in Korea since
the 1990s [27] and increased in prevalence among all
strains significantly between 2002 and 2005, peaking at
50% in 2004 [27-30]. These epidemic A-B+ strains
belonged to ribotype group 017 and were widespread in
Korea [27,28,31]. Subtyping of 017 strains revealed six dif-
ferent PFGE pulsotypes and 13 restriction fragment length
polymorphism-based subtypes [32]. Shin et al. reported
that 72% of PMC cases between 2006 and 2010 were
caused by A-B+ strains [29]. Ribotype 018 was the most
prevalent strain isolated in Seoul from September 2008 to
January 2010 [33]. Ribotype 027 was detected in 2006 [34]
in a hospital-associated case of PMC but has failed toproliferate in Korea [19]. Type 078 was reported as the
most common (3.1%) binary toxin-positive strain [31].
China
The lack of reports on CDI from mainland China con-
trasts with the relatively large number of reports from
neighbouring Korea and Japan. An English language re-
view of the Chinese language literature found two stud-
ies from Southern China in general hospital patients
with 21/183 patients (1994–1997) and 13/257 patients
(reported in 2006) with CDI (no diagnostic criteria
reported). Another study from Beijing identified 36 cases
among 71,428 in-patients from 1998 to 2001 [35]. Fur-
ther studies were limited to special groups of patients
with malignancy and those receiving chemotherapy or
stem cell transplantation, with incidence rates varying
from 1.6% to 3.5%, with an exceptionally high rate (27%)
reported in the stem cell transplant patient study [35].
In most studies a sampling frame was not reported
which, in view of the low rate of testing in China, makes
assessment of the true incidence of CDI impossible [35].
The most comprehensive Chinese study of CDI was
conducted between March 2007 and April 2008 at a
1,216 bed hospital in Shanghai [36-38]. During the study
period, 42,936 patients were discharged and 587 patients
had stool samples submitted for testing by toxin assay
and culture [36]. Overall the incidence of CDI was 17.1
per 10,000 admissions [37]. CDI was mild, possibly due
to the younger mean age of patients (62.8 years) com-
pared with a large European survey where 63% were ≥65
years [20]. Fifty-six isolates from this study were aggre-
gated with further unspecified isolates to create a collec-
tion of 75 [38]. The most common ribotypes were 017,
012 and 046 (Figure 1).
In the absence of ribotyping studies other than that of
Huang et al., a recent report of MLST typing on 69 C.
difficile strains mainly from Beijing provides some fur-
ther insight on the molecular epidemiology of CDI in
China [41]. The equivalent ribotypes of the most com-
mon sequence types (ST37, ST35, ST54) found were 017
(23%), 046 (23%) and 012 (17%), respectively [42]. The
collection included 16 Guangzhou isolates from the
1980s comprised of the ribotype equivalents: 017 (9 iso-
lates), 046 (1 isolate), 020 (5 isolates) and ST119 (1 iso-
late). This suggests that ribotypes 017, 046 and perhaps
012 are the most common in mainland China, a pattern
that differs to other world regions.
Taiwan
A similar situation to Japan and China is found in
Taiwan, where testing is rare so the true incidence of
CDI cannot be defined. The number of CDI cases in-
creased by 5–6 times in patients ≥65 years between 2003
and 2007 according to one study [43]. Increasing
Figure 1 Ribotype distributions for studies in China (A,B), Hong Kong (C), Japan (D-G) and Korea (H-K). A: n = 75 isolates collected in
2008; 33 ribotypes identified [37]. B: n = 110, December 2008-May 2009; 16 ribotypes [39]. C: n = 345, 2009; 106 ribotypes [40]. D: n = 87, March
1996-November 1999; 12 ribotypes [8]. E: n = 148, November 1999-October 2004; 26 ribotypes [16]. F: n = 71, April 2005-March 2008; 20 ribotypes
[14]. G: n = 87, 2003–2007; 18 ribotypes [17]. H: n = 187, 1980–2006; 39 ribotypes [27]. I: n = 105, 1995–2008; 11 ribotypes [32]. J: n = 337 toxigenic
isolates, 2006–2008; 50 ribotypes [31]. K: n = 194, 2009–2010; 54 ribotypes [19].
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matic rise, as another report by Chan et al. demon-
strates. They found the proportion of positive cultures
remained constant at ~10% while testing increased from
2002 to 2009 as awareness of CDI increased [44]. The
incidence rate found at a northern Taiwan hospital was
0.45/1,000 patient days overall, and 7.9/1,000 patient
days in ICU wards [45]. Ribotype 017 strains were found
(6%) in a sample of 142 Taiwanese isolates where 57
ribotypes were identified [46], however other inter-
nationally recognised ribotypes of Taiwanese isolates
have not been reported. While binary toxin-positive iso-
lates were detected, ribotypes 027 and 078 have not been
reported from Taiwan [47].
Hong Kong
CDI has been better recognised and studied for longer
in Hong Kong than in mainland China and Taiwan. A
survey at Queen Mary Hospital, Hong Kong in 1996–7
reported 100/3,112 patients with diarrhoea positive by
culture for C. difficile [48]. A more recent survey at thesame hospital using a tissue culture cytotoxin assay be-
tween September and December 2008 detected 37/723
positive samples [49]. The number of patients diagnosed
in 2003 was 82 compared to 66 in 2008, suggesting the
overall number of cases was constant. Testing for CDI
increased following the isolation of ribotype 027 among
one of 12 hyper-toxigenic (detectable cytotoxin at 100-
fold dilution) isolates identified in a 3-month study in a
university hospital in 2008 [49].
There are little data on ribotyping in Hong Kong, the
most comprehensive being a retrospective study of 345
isolates from 307 patients in 2009 from a healthcare re-
gion spanning five hospitals. Unusually, 70% were of a
pattern not represented by 23 of the most internationally
common ribotypes, with a further 11.6% being non-
typable (Figure 1) [40]. Ribotype 002 represented 9.4% of
strains, presumed to be causing cross-infection as the
incidence between 2004 and 2008 was 0.53/1,000 admis-
sions rising in 2009 to 0.95/1,000 admissions. An ele-
vated frequency of sporulation (20.2%) was found in 35
of these ribotype 002 isolates compared to 3.7% for 56
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Ribotype 017 strains were also found at a prevalence of
0.7% [40]. Ribotype 027 was first detected in 2008 in
stool of a patient on steroids with no history of travel in
the previous 1.5 years and, as yet, there have been no
further reports of 027 from Hong Kong [49].
Southeast Asia
Philippines
The underestimation of the role of C. difficile in enteric
disease in Asia was demonstrated recently by a study in
the Philippines. Historically, patients with colitis were di-
agnosed with amoebic colitis, presumed to be caused by
Entamoeba histolytica. However, 43.6% of colitis cases
were positive for C. difficile when testing by enzyme im-
munoassay (EIA) for toxin A/B was introduced [50].
Given that metronidazole is the standard treatment for
both CDI and amoebic colitis, CDI would be masked if
testing was not carried out.
Thailand
In the earliest report of CDI in Thailand in 1990, faecal
cytotoxin was detected in 52.5% of 206 diarrhoeal pa-
tients while culture gave low recovery rates (4.8%) over a
26-month period. Cytotoxin was detected in stool of
61% of antibiotic-treated patients, and 51% of non-
antibiotic-treated patients [51]. In contrast, Thamlikitkul
et al. reported low detection of toxin A by EIA in
clindamycin-treated (10/140 patients) and patients
treated with beta-lactams (10/140) [52]. The difference
in prevalence found in both studies was probably due to
the use of different toxin assays.
The prevalence of C. difficile in antibiotic-associated
diarrhoea (AAD) patients was reported as 18.64% by cul-
ture and 44-46% by PCR for tcdA and tcdB on the same
stool samples, showing the need for both culture and
testing for presence of toxin [53]. Similarly, a recent
study in Bangkok found that combining toxin EIAs with
direct tcdB PCR on stool increased positive diagnoses
two-fold, compared with toxin EIAs alone [54].
Wongwanich et al. found a greater prevalence of CDI
in 201 HIV-positive patients (58.8%) than in 271 HIV-
negative patients (36.5%), and six PFGE subtypes were
found [55]. Again, toxin A EIA alone gave lower preva-
lence than when combined with culture. Another study
on AIDS patients where only toxin A EIA was perfor-
med reported a lower prevalence of CDI (16/102 pa-
tients) [56]. The discrepancies between studies where
lower prevalence is reported when a toxin A assay alone
was used suggest it is likely that toxin A-negative strains
were widespread.
Wongwanich et al. reported on a collection of 77 C.
difficile isolates from 44 asymptomatic children and in-
fants, and 33 diarrhoeal adult patients. In this study,tcdA PCR-negative isolates predominated, numbering 57
overall and 18/33 adult diarrhoeal isolates. Fourteen
PFGE pulsotypes and eight subtypes were found [57].
No data on circulating ribotypes have been reported.
Malaysia
Reports of CDI in Malaysia are rare. In the most inform-
ative study in Malaysia to date, toxin A/B assays on 175
stool samples from inpatients with AAD were performed
in a tertiary hospital in north-eastern Malaysia. Twenty-
four (13.7%) were positive for toxin, with the majority of
infected patients aged >50 years [58]. No ribotyping or
other molecular analysis has been reported on Malaysian
C. difficile isolates.
Indonesia
Like Malaysia, reports on CDI in Indonesia are uncom-
mon. An aetiology study of diarrhoea in Indonesian chil-
dren identified C. difficile in 1.3% of stool samples
tested. Toxin A EIA only was performed so the true
prevalence of C. difficile may have been greater [59]. The
only molecular study included eight isolates from
Indonesia, five of which were toxinotype VIII and ribotype
017, and grouped with international 017 epidemic strains.
Two were A+B+ toxinotype 0, and one A-B+ isolate was
binary toxin-positive, toxinotype XVI [15].
Singapore
A 50-month aetiological study (1985 to 1989) of diarrhoea
in 4,508 patients at the National University Hospital found
C. difficile in 35 of only 365 cases where C. difficile culture
was requested. The incidence rate of CDI in Singapore
General Hospital was 3.2/1,000 admissions, more com-
mon in males and patients >50 years. Culture of stool
samples identified cases (43%) which were negative by
toxin A/B EIA. CDI was three times more common in
Malay patients than in patients of Indian heritage [60]. An
increase in incidence of CDI was observed in a 1,200 bed
general hospital from 2001 to 2006. The incidence rate
rose from 1.49 cases per 10,000 patient days to 6.64 per
10,000 patient days, with a concurrent increase in positive
toxin assays on stool [61]. A broader surveillance study in
three hospitals found that CDI incidence decreased from
0.52/1,000 patient days in 2006 to 0.3/1,000 patient days
in 2008, as testing increased over the same time period
[62]. Binary toxin-positive strains have been reported, in-




An early report found 21/93 AAD cases were positive
for C. difficile by culture and toxin assay in Nehru
Hospital in 1983–1984 [64]. In Calcutta, C. difficile was
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rhoea over 1 year [65]. A hospital in Delhi reported CDI
in 26/156 diarrhoeal hospitalised patients, detected by
culture and toxin A EIA [66]. Infection control measures
subsequently introduced at this hospital apparently re-
duced incidence of CDI by more than 50% over 5 years
[67]. A retrospective review by Ingle et al. in a Mumbai
hospital found 17/99 patients between 2006 and 2008
were diagnosed with CDI by toxin A/B EIA [68]. The
most recent report found a prevalence of non-toxigenic
C. difficile of 12.6% among 79 hospitalised patients, five
of whom subsequently developed diarrhoea with positive
culture and toxin assay. The study group also detected
widespread contamination of surfaces on beds (51%) and
hands of hospital workers (62.5%) [69]. Several reports
exist of acute diarrhoea in hospitalised children (7-11%)
caused by C. difficile [70-72]. The molecular epidemiology
of C. difficile strains in India is not currently known.
Bangladesh
In the 1990s, an aetiological study found that 13/814
children admitted to hospital with diarrhoea were
infected with C. difficile (diagnosed by cell cytotoxin
assay). Seven of the cases were concurrently infected
with another diarrhoeal agent [73]. Recent reports are
not available for Bangladesh.
Epidemiology
Prevalent C. difficile ribotypes in Asia
Ribotyping data with internationally recognised nomen-
clature are available for China, Japan, Singapore, Hong
Kong, Taiwan, and Korea. Overall, the most prevalent
ribotypes in Asia appear to be 017, 018, 014, 002, and
001. While ribotypes 027 and 078 have caused outbreaks
in North America and Europe, they are reported only to
have caused sporadic cases of CDI in Asia so far, in
Singapore, Hong Kong, Korea, and Japan [16,34,40,46,
49,63,74]. Ribotype 078 has only been reported from
Korea and China to date [31,37]. Another binary toxin-
positive strain, ribotype 130, was recently reported from
Korea [19].
Meanwhile, ribotype 017, A-B+, toxinotype VIII strains
are widespread in Asia, and have caused epidemics
worldwide (Figure 1). In China and Korea 017 is the
most common ribotype in circulation, and is prevalent
in Japan, Taiwan, and Hong Kong also [31,32,36,39]. Ex-
posure to antineoplastic agents, use of nasal feeding
tubes, and care in a particular hospital ward were associ-
ated with infection with 017 strains in one hospital in
Japan [11]. Ribotype 017 strains have persisted in China
and Taiwan while they appear to have declined in Korea
(Figure 1).
In Japan, smz/018 appears to have persisted as the
most common ribotype for over a decade (Figure 1).Ribotype smz/018 was the most prevalent strain isolated
in a tertiary hospital in Seoul between September 2008
and January 2010 [33], indicating spread from Japan to
Korea. Ribotype 018 caused outbreaks of CDI in Italy in
2007/2008 and is the fourth most prevalent ribotype in
Europe at present [20,21]. It is not clear whether smz/
018 is prevalent in other Asian countries, as comparative
typing with a reference smz or 018 strain may not have
been performed.
Ribotypes 017 and 018 have caused widespread disease
in Asia and across the world. Unlike the other major
epidemic strains 027 and 078, they do not produce bin-
ary toxin, and ribotype 018 does not appear to possess
variant toxin genes [21]. Some other virulence factors
may contribute to their spread. The resistance of ribotype
018 isolates to clindamycin and fluoroquinolones could
contribute to their enhanced virulence [8,33,40]. Another
virulence factor is high sporulation rate. The epidemic
ribotype 002 isolates in Hong Kong sporulated at a higher
rate than other isolates, allowing them to persist in the
hospital environment and cause outbreaks of disease [40].
Prevention and control
Two reports of infection control in Asian hospitals were
found. A hospital in India introduced control measures
including disinfection of surfaces, rapid detection of C.
difficile by toxin assays, isolation of patients, controls on
prescription of antibiotics and education of staff mem-
bers. The incidence of CDI (initially 15% among cases of
nosocomial diarrhoea) was reduced by 50% while the
number of tests requested increased as health workers
became more aware of CDI [67]. A hospital-wide
computerised antimicrobial stewardship scheme was in-
troduced in a hospital in Taiwan. While the incidence of
some antibiotic resistant organisms decreased, the isola-
tion rate of C. difficile remained constant at 10% [44],
indicating that other infection control measures besides
antimicrobial stewardship would be required to control
CDI in hospitals.
Asia is going through a period of rapid demographic
change. With its dense, growing population, infection
control is a pertinent issue. As C. difficile now causes the
majority of nosocomial disease in North America and Eur-
ope, control measures could be applied in Asia to prevent
the same situation there. A number of issues exist which
could contribute to the spread of CDI in Asia.
As wealth and the aged population are increasing,
more people have access to hospital care and enter aged
care facilities. It is likely that CDI incidence could in-
crease as these high-risk populations increase in size.
For example, modelling of the future age structure of
the Chinese population suggests that there will be a lar-
ger population at risk for CDI. Using census data from
2005 (population 1.3 billion) when only 100 million
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Antibiotic use in most Asian countries is poorly regu-
lated. A review of Southeast Asian countries found that
47% of pneumonia cases do not receive an appropriate
antibiotic, 54% of diarrhoea cases are unnecessarily
treated with antibiotics, and 40% of antibiotics are pre-
scribed in under-dose [76]. In many cases inappropriate
antibiotics are prescribed without any laboratory test.
Studies in India have found the most commonly pre-
scribed antibiotics for cough and respiratory disease are
fluoroquinolones, a known risk factor for CDI [76]. In
addition, antibiotics are freely available without prescrip-
tion in most Asian countries, leading to misuse in the
community.
Given the free use of antibiotics by the general public it
would be plausible that CA-CDI could be common in Asia.
Studies in Asian countries have neglected to address the
issue of CA-CDI, apart from two studies in Korea which
found conflicting proportions of 7% and 59% of all CDI
surveyed being community-acquired. It would be appropri-
ate to monitor CA-CDI more closely in Asia in the future.Table 1 Antimicrobial resistance rates and MIC values for Clo
(Reference) Number
of isolates
[Resistance rate] (%), MIC50 (mg/L), MIC90 (mg
Erythromycin Clindamycin Tetracycline Mo
China
[37] 75 [76], 128, 128 [66.7], 128,
128
[41.3], 4, 64 [45.














[31] 120 [50], 128,
>128
[42]
[19] 111 [82] [83]
[33] 131 [67.9] [82]
[78] 123 [75] [85]
Singapore
[60] 68 [63], 8, >512
Taiwan
[79] 60 [73.3], 16, 64 [41.7], 8, >16 [30]
[47] 113 [46], 4, >256 [16]
a 18 isolates showed heteroresistance to metronidazole, bsubset of 25 isolates testeDespite widespread antibiotic use few studies in Asia
have measured antimicrobial susceptibility of clinical C.
difficile isolates. High resistance rates to moxifloxacin,
and clindamycin have been found in isolates from Korea,
Japan, Northern Taiwan and China (Table 1). Heterore-
sistance to metronidazole has been reported from China,
warranting close monitoring (Table 1).
Production and consumption of meat products is also
increasing in Asia [80]. Intensive farming of poultry,
seafood and swine is already in place, and increasing
with worldwide demand [81]. The risk of C. difficile
colonisation and/or infection in animals would most
likely increase with intensive farming practices including
crowding of animals and prophylactic antibiotic use.
Thus contamination of food products and animal-
human transmission could occur. To date, no reports
have been made of C. difficile in the environment or
animals, apart from five cases of fulminant colitis
caused by ribotype 078 in thoroughbred racehorses in
Japan [82], and the isolation of C. difficile from 2/ 250
(0.8%) swine faecal samples from 25 pig farms, also in





3], 4, 128 [100], 64, 128 [0], <16/4,
16/4
[0], 0.25, 0.25 [0], 1, 2
8], 16, 128 [100], 64, 128 [0], 8/4, 16/4 [0]a, 0.125, 0.25 [0], 0.5, 1
[100] 0.5, 0.75 0.75, 1.5
[100], >32,
>32
[0], 0.19, 0.25 [0], 2, 4
b [100] [0] [0]
, 2, 16 [0], 8, 16 [0], 1,4 [0], 0.5, 1
[0] [0]
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According to the existing evidence, CDI occurs at simi-
lar rates in Asia as in other continents where CDI is
more commonly recognised and researched. The mo-
lecular epidemiology of C. difficile strains in Asia indi-
cates a persisting predominance of variant A-B+ ribotype
017 strains and ribotype 018 strains (Figure 1). Binary
toxin-positive strains have rarely been isolated to date
despite the proliferation of ribotypes 078 and 027 in
Europe and North America. Favouring toxin A EIAs for
diagnostic methods is not optimal for the Asian region
due to the predominance of A-B+ strains. Broader sur-
veillance monitoring CA-CDI and C. difficile in animals
will enhance our understanding of the epidemiology of
CDI in the region.
Conclusions
CDI is not widely recognised in Asia so in consequence
the extent of the disease is not known. Although rela-
tively few studies on C. difficile have been performed in
Asia, what work has been done demonstrates that CDI
is a significant cause of nosocomial disease in Asian
countries. It appears that awareness is increasing and
testing and surveillance are on the rise. Routine testing
is required to inform on the prevalence of CDI through-
out the region. The widespread prevalence of the 017
group of A-B+ strains in Asian countries shows that
assays for toxin B or the tcdB genes are preferable to
toxin A assays for diagnosis of CDI. The more virulent
epidemic strains 027 and 078 do not appear to have
become established in Asia, while ribotype 017 and
smz/018 strains have caused epidemics.
Widespread unregulated antibiotic use and inappropri-
ate prescribing in SE Asian countries indicates that CDI
could be widespread in those regions where surveillance
is currently lacking. Asia may be facing a “perfect storm”
as heavy usage of antibiotics combines with an ageing
increasingly hospitalised population. Increasing labora-
tory capacity in the region as well as improving sur-
veillance should be seen as essential in preventing
unnecessary morbidity and mortality.
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